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ttp://dx.doi.org/10.1016/j.jmoldx.2016.06.010Sequencing of tumor DNA to detect genetic aberrations is becoming increasingly important, not only to
reﬁne cancer diagnoses but also to predict response to targeted treatments. Next-generation sequencing
is widely adopted in diagnostics for the analyses of DNA extracted from routinely processed formalin-
ﬁxed, parafﬁn-embedded tissue, ﬁne-needle aspirates, or cytologic smears. PCR-based enrichment
strategies are usually required to obtain sufﬁcient read depth for reliable detection of genetic aberra-
tions. However, although the read depth relates to sensitivity and speciﬁcity, PCR duplicates generated
during target enrichment may result in overestimation of library complexity, which may result in false-
negative results. Here, we report the validation of a 23-gene panel covering 41 hotspot regions using
single-molecule tagging of DNA molecules by single-molecule molecular inversion probes (smMIPs),
allowing assessment of library complexity. The smMIP approach outperforms Sanger and Ampliseq-
Personal Genome Machineebased sequencing in our clinical diagnostic setting. Furthermore, single-
molecule tags allow consensus sequence read formation, allowing detection to 1% allele frequency and
reliable exclusion of variants to 3%. The number of false-positive calls is also markedly reduced
(>10-fold), and our panel design allows for distinction between true mutations and deamination arti-
facts. Not only is this technique superior, smMIP-based library preparation is also scalable, easy to
automate, and ﬂexible. We have thus implemented this approach for sequence analysis of clinical samples
in our routine diagnostic workﬂow. (J Mol Diagn 2016, 18: 851e863; http://dx.doi.org/10.1016/
j.jmoldx.2016.06.010)Supported by Maag Lever Darm Stichting (MLDS) research grant FP13-9.
Disclosures: None declared.The availability and requirement of molecular therapeutics
in routine cancer treatment has greatly increased over the
past decade. Combined with the stratiﬁcation of patients
amenable for targeted therapeutics based on the absence or
presence of speciﬁc genomic aberrations, this has increased
the requirement for genomic proﬁling of tumor specimens.1
Next-generation sequencing (NGS) allows for genomicstigative Pathology and the Association for M
Y-NC-ND license (http://creativecommons.orgcharacterization in a sensitive manner.2 Although whole
genome or exome sequencing both provide extensive
genomic information, targeted gene panels are currently best
ﬁt for tumor proﬁling in a routine clinical context. Itolecular Pathology. Published by Elsevier Inc.
/licenses/by-nc-nd/4.0).
Eijkelenboom et almatches best with the billable costs, short turn-around time
(TAT), and requirement for reliable detection of variants
compatible with routinely obtained material [formalin-ﬁxed,
parafﬁn-embedded (FFPE) tissue specimens, ﬁne-needle
aspirates, and cytologic smears].3e5 This requires sufﬁ-
cient read depth to detect or exclude low-frequent variants
that might be present due to tumor heterogeneity or a low
tumor load in the tissue specimen and a robust and reliable
bio-informatics pipeline. PCR-based ampliﬁcation is
commonly used to generate such targeted sequencing
libraries for NGS.6,7 Multiple genomic regions can be
ampliﬁed simultaneously (multiplex PCR) for analysis of
multiple genes from limited tissue material with low-quality
genomic DNA (gDNA), such as the FFPE samples routinely
used in molecular diagnostics. However, as a consequence
of this ampliﬁcation, true library complexity cannot be
determined, because PCR duplicate reads cannot be distin-
guished from independent reads originating from separate
original template molecules. This could result in over-
estimation of the actual number of DNA molecules
analyzed, risking false-negative calls, which is crucial in the
context of poor-quality samples with a small amount of
ampliﬁable DNA. Single-molecule tagging (SMT) has been
developed to overcome this issue by marking PCR dupli-
cates originating from the same template molecule, which
allows both a genuine analysis of library complexity and the
possibility to combine multiple sequencing reads from PCR
duplicates to generate a single consensus read.8e10 The
latter also allows ﬁltering for errors originating during li-
brary ampliﬁcation and sequencing that might result in
false-positive calls due to jackpotting events.
We sought to develop an NGS-based targeted approach in
a routine diagnostics setting for reliable detection of clini-
cally relevant variants in tissue samples from FFPE speci-
mens, in which multiplex analysis could be combined with
SMT technology. Recently, multiplex analysis and SMT
technology have been combined in single-molecule molec-
ular inversion probes (smMIPs) to detect low-frequent var-
iants in FFPE-derived DNA isolates in a simple, scalable,
and relatively cost-effective manner.11 In addition, the
strand-speciﬁc nature of ampliﬁcation by smMIPs can aid to
distinguish genuine C:G>T:A mutations from those
induced by cytosine deamination, a common artifact in
DNA recovered from FFPE-ﬁxed material.12 Here, we
describe the development, validation, and implementation of
a single comprehensive smMIP-based Cancer Hotspot Panel
(CHP) for mutation detection in clinically relevant genes.
Materials and Methods
Sample Preparation
Clinical specimens (generally from sections 3 20 mm) were
digested at 56C for at least 1 hour in the presence of TET-
lysis buffer (10 mmol/L Tris/HCl pH8.5, 1 mmol/L EDTA
pH8.0, 0.01% Tween-20) with 5% Chelex-100 (143 to 2832;852Bio-Rad, Hercules, CA), 15 mg/mL GlycoBlue (AM9516;
Thermo Fisher, Waltham, MA), and 400 mg proteinase K
(19133; Qiagen, Valencia, CA), followed by inactivation at
95C for 10 minutes. The supernatant was transferred after
centrifugation and to reduce the total volume for the robotized
protocol, cooled on ice and precipitated in the presence of
70% EtOH and 1/10 volume 3MNaAc (pH 5.2). Pellets were
washed with cold 70% EtOH and dissolved in 80 mL Tris-
EDTA, and DNA concentration was determined using the
Qubit Broad Range Kit (Q32853; Thermo Fisher). Control
DNA isolated from peripheral blood leukocytes was soni-
cated using a Covaris with a standard protocol to obtain 200-
bp fragments and analyzed on a 1% agarose gel with 100-bp
size ladder (15628-050; Invitrogen, Carlsbad, CA). The
control NGS sample was obtained from Horizon Discovery
(Waterbeach, UK; HD701).
Preparation of the smMIP-Pool for Targeted
Enrichment
MIPs were designed using the procedure described13 for all
hotspots (Table 1), in a tiling manner preferentially covering
all hotspots with two independent smMIPs targeting both
DNA strands. The sum of the targeting arms is 40 bp
(extension plus ligation probe arms) and the gap-ﬁll length
was set to 112 bp. The targeting arms were joined by a
common backbone sequence and a stretch of 8  N nu-
cleotides was inserted between the backbone and ligation
probe sequence (Supplemental Table S1). In case it was
unavoidable to design smMIPs without common single
nucleotide polymorphism variants in the respective capture
arms, smMIPs were designed recognizing both alleles. Al-
iquots of each oligonucleotide smMIP probe (produced by
Integrated DNA Technologies, Leuven, Belgium) were
mixed in an equimolar or corrected fashion (Supplemental
Table S1) to form the CHP smMIP-pool. The smMIP pool
was phosphorylated with 1 mL of T4 polynucleotide kinase
(M0201; New England Biolabs, Ipswich, MA) per 25 mL of
100 mmol/L smMIPs and ATP-containing T4 DNA ligase
buffer (B0202; New England Biolabs). The molecular ratio
between gDNA and smMIPs was set to 1:3200 for every
individual smMIP (and is thus independent of pool size),
and the required quantity of the smMIP pool was deter-
mined for a standard input of 100 ng gDNA.
Library Preparation
In manual experiments, a total of 100 ng of genomic DNA
was used as input in a 20-mL volume, unless otherwise
speciﬁed, with a total capture volume of 25 mL, including
the (diluted) phosphorylated smMIP pool, 1 unit of
Ampligase DNA ligase (A0110K; EpiBio, Madison, WI)
with Ampligase Buffer (A1905B, DNA ligase buffer), 3.2
units of Hemo Klentaq (M0332; New England Biolabs), and
8 mmol of dNTPs (28-4065-20/-12/-22/-32; GE Healthcare,
Little Chalfont, UK). After denaturation (95C for 10jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 An Overview of All Regions Targeted by the smMIP Panel, Including Gene Name, Transcript IDs from Refseq and Ensembl, and
Targeted Regions
Gene
Transcript ID
(RefSeq)
Transcript ID
(Ensembl)
Exon
number Targeted codons
Positions analyzed
for variants
AKT1 NM_005163 ENST00000555528 03 E17 c.47-5 to c.86
BRAF NM_004333 ENST00000288602 15 D594-K601 c.1742-5 to c.1845
CTNNB1 NM_001904 ENST00000349496 03 D32-S45 c.53 to c.146
EGFR NM_005228 ENST00000275493 12 S492 c.1392 to c.1498þ5
18 E709-G719 c.2062-5 to c.2184þ5
19 All codons (G729-D761) c.2185-5 to c.2283þ5
20 All codons (E762-K823) c.2284-5 to c.2469þ5
21 L858eL861 c.2245 to c.2630
ERBB2 NM_004448 ENST00000269571 20 Y772eY781 c.2308-1 to c.2357
GNA11 NM_002067 ENST00000078429 04 R183 c.495 to c.582
05 Q209 c.606-5 to c.669
GNAQ NM_002072 ENST00000286548 04 R183 c.540 to c.605þ5
05 Q209 c.606-1 to c.650
GNAS NM_000516 ENST00000371085 08 R201 c.587 to c.635
09 Q227 c.660-5 to c.716
H3F3A NM_002107 ENST00000366815 02 K28, G35 c.49 to c.128þ5
H3F3B NM_005324 ENST00000254810 02 K37 c.38 to c.128þ5
HRAS NM_005343 ENST00000451590 02 G12, G13 c.17 to c.83
03 A59, Q61 c.128 to c.227
IDH1 NM_005896 ENST00000345146 04 R132 c.351 to c.410
IDH2 NM_002168 ENST00000330062 04 R140, R172 c.409 to c.518
JAK2 NM_004972 ENST00000381652 14 V617 c.1780 to c.1864þ5
KIT NM_000222 ENST00000288135 08 All codons (K412-Q448) c.1232-5 to c.1346þ5
09 All codons (C450-K513) c.1347-5 to c.1540þ5
11 All codons (K550-F591) c.1648-5 to c.1774þ5
13 K642-N655 c.1880-1 to c.1990þ5
14 All codons (P665-S713) c.1991-5 to c.2141þ5
17 D816-Y823 c.2395 to c.2484þ5
KRAS NM_004985 ENST00000311936 02 G12, G13 c.9 to c.71
03 A59, Q61 c.122 to c.215
04 K117, A146 c.291-5 to c.357 and
c.402 to c.450þ5
MPL NM_005373 ENST00000372470 10 W515 c.1526 to c.1565þ5
MYD88 NM_002468 ENST000003696334 05 L265 c.776-5 to c.840
NRAS NM_002524 ENST00000369535 02 G12, G13 c.-17-5 to c.64
03 A59, Q61 c.161 to c.245
04 K117, A146 c.312 to c.450þ5
PDGFRA NM_006206 ENST00000257290 12 All codons (K552-L595) c.1654-5 to c.1786þ5
14 All codons (T632-S667) c.1892-5 to c.2002þ5
18 V824-D842 c.2440-5 to c.2544
PIK3CA NM_006218 ENST00000263967 10 E542-Q546 c.1558 to c.1664þ5
21 M1043-G1049 c.3058 to c.3207þ10
ID, identiﬁcation; smMIP, single-molecule molecular inversion probe.
Cancer Hotspot Detection Using smMIPsminutes) the mix was incubated for probe hybridization,
extension, and ligation at 60C for 18 hours and cooled
before exonuclease treatment. Exonuclease I (10 units;
M0293; New England Biolabs) and III (50 units; M0206;
New England Biolabs) and Ampligase Buffer (see above)
were added to the capture volume, adding up to a total of 27
mL, and incubated for 45 minutes at 37C, followed by
inactivation at 95C for 2 minutes. A total of 10 mL of the
exonuclease-treated capture was used for PCR in a total
volume of 25 mL with 25 nmol common forward primer andThe Journal of Molecular Diagnostics - jmd.amjpathol.orgbarcoded reverse primers13 and iProof high-ﬁdelity master
mix (1725310; Bio-Rad). The resulting PCR products were
pooled before puriﬁcation with 0.8 volume of Agencourt
Ampure XP Beads (A63881; Beckman Coulter, Brea, CA).
Semiautomated library preparation was performed as
described (K. Neveling, A.R. Mensenkamp, R.C. Derks,
et al, unpublished data). In short, hybridization reactions
were pipetted using a Microlab STARplus robot (Hamilton,
Reno, NV). The exonuclease treatment was performed
manually to prevent exonuclease contamination in the853
Eijkelenboom et alpre- and post-PCR environments. The post-hybridization
PCR was performed using a MicroLab STARlet Replicator
Robot (Hamilton). All samples were subsequently pooled
on a MicroLab Starlet Replicator Robot (Hamilton). The
automated workﬂow contained the following modiﬁcations
compared with the manual protocol above: the maximum
input volume of gDNA was reduced to 7 mL to allow reli-
able pipetting of other reagents, requiring precipitation of
gDNA to accommodate for this smaller input volume.
Samples with concentrations >30 ng/mL were diluted to
obtain a ﬁnal concentration within the 15 to 30 ng/uL range,
resulting in approximately 100 to 200 ng of gDNA input per
smMIP capture. A total of 20 mL from the exonuclease-
treated capture mixture was used for PCR in a total volume
of 50 mL. Note that the gDNA:smMIP ratio as previously
described (K. Neveling, A.R. Mensenkamp, R.C. Derks,
et al, unpublished data) was set to 800:1 for high-quality
blood-derived gDNA, whereas 3200:1 was used for the
FFPE-derived DNA from clinical specimens in the present
study.
Sequencing
The puriﬁed libraries were denatured and diluted to a con-
centration of 1.2 pmol/L. Sequencing was performed on a
NextSeq500 instrument (Illumina, San Diego, CA) accord-
ing to the manufacturer’s protocol (300 cycles Mid Output
sequencing kit, v2), resulting in 2  150 bp paired-end
reads.
Data Analysis
Using the sample sheet, Bcl to fastq conversion and
demultiplexing of barcoded reads was performed automati-
cally (K. Neveling, A.R. Mensenkamp, R.C. Derks, et al,
unpublished data) and uploaded to a server running the
commercial analysis software (Sequence Pilot version 4.2.0;
JSI medical systems, Ettenheim, Germany). Single-mole-
culeedirected assembly of duplicate reads to generate
consensus reads after alignment was performed in a package
developed in collaboration with JSI medical systems (from
version 4.2.0, build 503 and onward). The following settings
were used for single-moleculeedirected consensus: Tags
active, yes; R1 tag length, 8; R2 tag length, 0; Min abs. cov.
cons., 1; Min per. cov. cons., 50%; Ignore cons. read thresh.,
30; Ignore N tags, yes, and Ignore low Qs tags, yes. Proper
identiﬁcation of sequence variants greatly relies on the var-
iables for variant calling, such as the minimal number of
mutant unique smMIPs (>2 in our settings) and the minimal
mutant allele frequency (1%). The following settings were
used for variant calling using Sequence Pilot: Required
Coverage/Min abs. cov., 40 combined; Mutations/Min abs.
cov., 5 combined; Min % cov., 1% per dir. Note that one
unique smMIP generates both a forward and a reverse read,
thus providing a read depth of 2 reads using this software
package. PIK3CA pseudogene reads were removed from the854alignment and subsequent analysis. After variant calling
using the commercial software, all variants were manually
inspected and curated. GraphPad Prism 5 (GraphPad Inc.,
San Diego, CA) was used for graphical presentation. All
smMIP analyses were performed in duplicate, resulting in
similar results, of which one representative is shown.
Routine Sequencing Method for Parallel Analysis
The smMIP approach was compared with our previous
routine sequencing approach, which consists of Sanger
sequencing for CTNNB1, GNAS, IDH1, IDH2, and MYD88
(Supplemental Table S1) and Ampliseq-based NGS using
the Personal Genome Machine (PGM; Thermo Fisher) for
relevant codons in AKT1, BRAF, EGFR, ERBB2 (HER2),
KRAS, NRAS, and PIK3CA (colon carcinoma/non-small cell
lung carcinoma custom panel) or AKT1, BRAF, GNA11,
GNAQ, HRAS, KIT, NRAS, and PDGFRA (melanoma/
gastrointestinal stromal tumor custom panel) (Supplemental
Table S1) according to the manufacturer’s protocol. Data
were analyzed with the same commercial software
(Sequence Pilot; JSI medical systems) and similar settings
for variant calling, with the exception of the single-
moleculeedirected building of consensus reads.
Results
Validation Plan
We aimed to design a single CHP of smMIPs targeting all
clinically relevant coding sequences in 23 genes, covering a
total of 41 hotspot regions and surrounding sequences (adding
up to a total of approximately 4.0 kb), to replace all our routine
Ampliseq/PGM NGS approaches and Sanger-based
sequencing analyses of oncogenes required for cancer di-
agnoses and/or predictive diagnostics (Table 1). We formu-
lated the procedure and requirements before we started the
implementation and validation, according to our quality
guidelines. The following requirements were deﬁned:
i) >95% of all hotspot regions should be covered by a min-
imum of two independent smMIPs, preferably targeting both
DNA strands; ii) analysis of all 41 hotspot regions should be
performed in one single reaction, with uniform read depth
distribution (the average read depth for >90% of targets may
vary up to 1 order of magnitude); iii) the detection of variants
should be comparable or better compared with our routine
diagnostic Ampliseq/PGM and Sanger approach; iv) while
the number of false-positive variant calls, and v) the number
of sample drop-outs should be comparable or smaller; vi) in a
routine diagnostic setting TAT of >90% of clinical requests
should be 7 working days.
smMIP Panel Design
Targeted enrichment on isolated DNA using smMIPs relies
on a three-step protocol, which can be completed within 24jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 1 Schematic overview of the smMIP
technique. A: smMIPs are long oligonucleotides
consisting of two targeting arms, the extension
probe and the ligation probe, adding up to a total
of 40 bp in length, joined by a backbone including
an 8-bp SMT (orange). The probe sequences are
complementary to the sequences surrounding the
targeting region (112 bp in our setup). smMIPs
targeting all clinically relevant hotspots were
designed for our panel of 23 genes and pooled.
Note that for graphical representation, the smMIP
segments and targeted region are not to scale. B:
During the capture reaction, the pooled smMIP
mixture is hybridized to gDNA, followed by gap-
ﬁlling through extension (using the targeted re-
gion as template) and ligation, resulting in smMIP
circulation. Subsequent exo-nuclease treatment
(indicated by yellow pac-man symbols) removes
all linear DNA, whereas the single-stranded circular
smMIPs remain. These are ampliﬁed by PCR using
primers recognizing sequences in the backbone
(green); primers include sample-indexing/
barcoding (purple) for sample-multiplex next-
generation sequencing analysis. C: Schematic ﬂow
of consensus read building directed by single-
molecule tags. smMIP library PCR molecules
include both probe sequences (black), the SMT
(two example sequences are depicted), and the
copied target sequence, of which the left example
contains a variant (depicted by a black bar). After
sequencing reads are aligned using the probe se-
quences (1) and then reads sharing the same
unique SMT (thus originating from the same cap-
ture event) are merged (2) into a consensus read
sequence (3). This also results in loss of
sequencing variants due to PCR and sequencing
artifacts (gray vertical stripes); however, genuine
mutations present in the genomic template are
maintained (black vertical stripes). gDNA,
genomic DNA; smMIP, singe-molecule molecular
inversion probe; SMT, single-molecule tagging.
Adapted with permission from Cold Spring Harbor
Laboratory Press.11
Cancer Hotspot Detection Using smMIPshours (Figure 1, A and B), followed by sequencing using the
NextSeq500 sequencer. The sequence reads are subsequently
aligned, and PCR duplicates are joined to form a consensus
whenmarked by an identical single-molecule tag (Figure 1C),
which results in a unique read depth excluding PCR dupli-
cates and provides a measure for library complexity. The
single-molecule tag of eight random nucleotides can uniquely
mark 65,536 molecules (48) per amplicon, which roughly
equals a total of 200 ng of gDNA. To prevent allelic drop outThe Journal of Molecular Diagnostics - jmd.amjpathol.orgdue to genomic variation in the smMIP binding sites, smMIPs
were designed to probe the target region in a tiling manner,
preferably in both orientations, thus capturing both strands.
Common single nucleotide polymorphisms in genomic se-
quences recognized by the probes were taken into account by
designing two smMIPs recognizing either the major or the
minor allele. Finally, smMIPs targeting X chromosomal
AMELX and Y-chromosomal AMELY genes to provide a sex
control were also included, which resulted in a panel of 120855
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856smMIPs (Supplemental Table S1), targeting all relevant co-
dons, with double tiling of 39 of 41 hotspot regions (95.1%),
thus fulﬁlling requirement i.smMIP Panel Performance
To evaluate the performance of our design, all smMIPs
were pooled in an equimolar fashion and tested using
archived gDNA isolated from four peripheral blood
samples and 10 clinical FFPE specimens with DNA
concentrations to 3 ng/mL (Supplemental Table S2). All
targeted regions were indeed captured and sequenced,
although with varying efﬁciency within and between
samples (Figure 2A). Overall, the average read depth of
all hotspot regions is within 1 order of magnitude for all
FFPE samples combined (Figure 2B), and this also holds
true for the 5% to 95% range of all hotspot regions for 8
of 10 FFPE-derived samples, with the two exceptions
being the oldest samples, of which DNA has been stored
at 20C for 2 and 4 years, respectively (Figure 2A).
When testing the same smMIP pool on high-quality
gDNA isolated from peripheral blood, a subset of
smMIPs captured their targets less efﬁciently relative to
the total smMIP pool. This was most prevalent in a subset
of smMIPs with the highest guanine-cytosine content and
can possibly be attributed to the fragmented nature of
FFPE-isolated gDNA because it is corrected by frag-
mentation (Supplemental Figure S1). Although all hotspot
regions are sufﬁciently covered in FFPE- and peripheral
blood-derived gDNA, we attempted to boost the perfor-
mance of 10 underperforming smMIPs by increasing their
concentration in the smMIP pool. This indeed resulted in
a signiﬁcant increase in unique read depth for 5 of 10
smMIPs. Taken together, these data show that uniform
sequence analysis of all 41 hotspot regions using smMIPs
can be performed in a single capture reaction on gDNA of
both poor and high quality (requirement ii).
We subsequently assessed if all types of clinically relevant
variants are detected using the smMIP-based enrichment.
Because the smMIPs target regions of exactly 112 bp, we
anticipated that insertions or deletions (>10 bp) might be
challenging to capture using smMIPs. We thereforeFigure 2 Single-reaction sequence analysis of all 41 hotspot regions
using smMIPs. A: Sequencing libraries were prepared using an equimolar
pool of all smMIPs on 10 clinical FFPE-derived gDNA samples (Supplemental
Table S2), followed by next-generation sequencing. Consensus reads were
generated and the minimal unique read depth at the relevant codons of all
41 hotspot regions was determined. B: The median unique read depth was
set to 1 to correct for differences in sequencing depth per sample. Sub-
sequently, the average median-corrected unique read depth of all FFPE
samples was calculated for all hotspot regions. The graph depicts the
normalized unique read depth per hotspot sorted by performance. Data are
expressed as box plots with 5th to 95th percentile whiskers with the ratio
between the 95th and 5th percentile values above each box plot (A). FFPE,
formalin-ﬁxed, parafﬁn-embedded; gDNA, genomic DNA; smMIP, singe-
molecule molecular inversion probe.
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Figure 3 Detection of clinically relevant mutations with the smMIP strategy. A: An overview of all different variants that have been identiﬁed in the
process of implementation and validation of the smMIP strategy. To the left the number of different variants organized per mutation type. In addition, the size
range of all mutations is indicated. To the right, a graphical representation of all identiﬁed mutations in KIT exon 11 is shown, with matching colors rep-
resenting mutation type. The targeted sequences surrounding exon 11 are represented by arrows for each smMIP, with the arrowhead representing the
orientation. B: The detected allele frequency in a commercially available reference sample (Horizon standard) was depicted for all 11 identiﬁed mutations,
relative to the reported allele frequency (Pearson’s correlation, two-tailed test, r and P values are depicted). C: Two FFPE-derived samples harboring a total of
three mutations [KIT: c. 1669_1683del (39% mutant allele), NRAS: c.181C>A (47%), and PIK3CA: c.1633G>A (27%)] were mixed according to the ratios
depicted below the graph. The detected and calculated allele frequencies (the latter by combining undiluted allele frequencies and mixing ratios) are shown
(Pearson’s correlation of all detected versus all calculated frequencies, two-tailed test, r and P values are depicted). D: Two FFPE-derived gDNA samples
harboring a mutation in KIT (#1) and NRAS (#2), respectively, were serially diluted before library preparation. The total amount of gDNA input is shown below
the graph. The left graph indicates the detected allele frequencies of the mutations at different amounts of input DNA, whereas the right graph depicts the
total number of identiﬁed unique reads containing the mutation at different amounts of input DNA. E: Parallel sequencing analysis was performed in a clinical
diagnostic setting for a total of 67 samples over a period of 6 weeks. Mutant allele frequencies are depicted, as detected by the Ampliseq-PGM approach
(Sanger-based analyses are excluded) and the smMIP-NextSeq500 approach (Pearson’s correlation, two-tailed test, r and P values are depicted). The outlier
indicated by the arrow represents a mutation in KIT: c.1684_1728del (estimated tumor load is 70%). FFPE, formalin-ﬁxed, parafﬁn-embedded; gDNA, genomic
DNA; PGM, Personal Genome Machin; smMIP, singe-molecule molecular inversion probe.
Cancer Hotspot Detection Using smMIPsspeciﬁcally tested 20 archived DNA specimens that were
previously shown to harbor duplications (up to 42 bp) and
deletions (up to 63 bp) in our routine diagnostic analysis. All
20 variations previously detected in these samples by other
methods were conﬁrmed using the smMIP analysis
(Supplemental Table S3). Furthermore, during the process of
implementation and validation we analyzed >200 samples
using smMIPs parallel to Sanger sequencing or Ampliseq-
based sequencing. During this period we veriﬁed all muta-
tions, that is, a variety of substitutions, deletions, insertions,
and complex rearrangements, using smMIPs (Figure 3A,
Supplemental Table S3). Combined, our data show that
clinically relevant genetic variants identiﬁed by different
sequencing methods (Sanger-based and AmpliSeq-
PGMebased) are also identiﬁed by the smMIP strategy
(requirement iii). These include point mutations, duplications
(up to 42 bp), deletions (up to 63 bp), and more complex
deletion-insertion mutations.
Although these initial test variables were established
using a manual protocol, further testing was performed in
parallel with the implementation of a fully automated li-
brary preparation as described for blood-derived gDNA
(K. Neveling, A.R. Mensenkamp, R.C. Derks, et al,The Journal of Molecular Diagnostics - jmd.amjpathol.orgunpublished data; with some adaptations described in
Materials and Methods). Advantages of an automated
strategy are that it facilitates library preparation of a
larger number of specimens and minimizes manual
errors during sample handling. In addition, a bio-
informatics pipeline was implemented to automatically
initiate data analyses on availability of raw sequencing
data. The robotized smMIP strategy was ﬁrst assessed for
the sensitivity of mutation detection using a commercially
available sample (Horizon Discovery standard) harboring
11 different mutations with varying allele frequencies. All
of these variants were detected with nearly identical
mutant allele frequencies as reported (Figure 3B and
Supplemental Table S4). In addition, DNA isolated
from two FFPE samples containing two different muta-
tions were mixed in different ratios, thereby diluting the
mutant alleles. The detected allele frequencies at different
mix ratios nicely agree with the calculated allele fre-
quencies (Figure 3C), demonstrating the accuracy and
linear range in the detection of mutant alleles by the
smMIP approach.
Dilution experiments to establish the optimal and minimal
amounts of required input DNA for smMIP-based857
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Figure 4 False-positive variants in sequencing analysis. A: The number of false-positive variants per sample with an allele frequency 5% as identiﬁed by
parallel sequencing analysis is depicted for both the Ampliseq-PGM and the smMIP-NextSeq500 approach. False-positive variants are deﬁned as all variants
excluding true positive variants, that is, known pathogenic variants (generally identiﬁed by both methods) and known nonpathogenic variants with estab-
lished minor allele frequencies. Only samples with sufﬁcient read depth for variant allele detection of all targets in single analysis using both next-generation
sequencing methods were included. B: The number of false-positive variants per read as identiﬁed by the smMIP approach is determined for the previously
described set of 10 FFPE gDNA samples (Figure 2 and Supplemental Table S2), either with and without the SMT feature used during data analysis. The bars thus
indicate the number of false-positive variants per unique read (Z SMT derived consensus) and all sequence reads, respectively. Above the bars the conse-
quence of SMT usage depicted by a fold decrease in false-positive variant frequency. C: The strand-speciﬁc nature of target recognition by smMIPs is rep-
resented in the left illustration, with smMIPs recognizing either the forward (þ smMIPs) or the reverse DNA strand ( smMIPs). Five examples of transitions
identiﬁed in clinical samples are depicted, including the affected gene, mutated position, and associated consequence for amino acid sequence. The per-
centage above the line represents the mutant allele frequency as detected by the þ smMIPs, the percentage below represents the allele frequency from the 
smMIP analysis. Because cytosine deamination induces sequencing artifacts only in the cytosine-containing strand, the imbalance can discriminate genuine
C:G>T:A mutations (on the right) from artifacts (on the left). ****P < 0.0001. FFPE, formalin-ﬁxed, parafﬁn-embedded; gDNA, genomic DNA; PGM, Personal
Genome Machin; smMIP, singe-molecule molecular inversion probe; SMT, single molecule tagging.
Eijkelenboom et alsequencing showed an optimum in obtained unique read
depth between 100 and 200 ng of input DNA (data not
shown). As expected, serial dilutions of two FFPE-derived
DNA samples in water showed a decrease in the number of
captured unique (mutant) reads with decreasing amounts of
total input DNA, indicating that the absolute amount of
gDNA is limiting. However, although the amount of input
DNA is decreased (to 19 ng of total input DNA in our
protocol, which equals 2.7 ng/mL), the variants are consis-
tently detected in these dilutions, with identical allele fre-
quencies (Figure 3D). This demonstrates that smMIP-based
sequencing is robust and also compatible with samples with
low DNA concentrations (<10 ng/mL). It also shows that
library complexity is proportionate to the amount of input
DNA.858Validation
Validation of the performance of the smMIP-based enrich-
ment, coupled with NextSeq 500-based sequencing (referred
to as the smMIP-NextSeq500 approach), including an
automated protocol in the routine diagnostic workﬂow, was
performed in parallel to our routine NGS approach (the
AmpliSeq-PGM strategy) and Sanger-based sequencing
analysis. These methods were tested in parallel for 6 weeks,
mainly to evaluate the smMIP strategy in the routine diag-
nostic workﬂow. All mutations identiﬁed in the Ampliseq-
PGM/Sanger diagnostic setting (total of 42) were also
identiﬁed using the smMIP-NextSeq500 approach. Two
additional mutations were detected using the smMIPs for
which the respective genes were not sequenced by ourjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 2 Speciﬁcations of the Ampliseq-PGM Strategy and the smMIP-NextSeq 500 Approach
Criterion Ampliseq-PGM smMIP-NextSeq 500 Deﬁnitions and formulas
TP 98 194 Variant calls: mutations and SNPs
FP 171 6 FP calls
TN 98186 204185 bp identical to reference genome
FN 0 0 Missed variants
Sensitivity
TP rate 100.000% 100.000% TP/(TPþFN)
FP rate 0.175% 0.003% FP/(FPþTN)
Accuracy 99.826% 99.997% (TPþTN)/(TPþTNþFPþFN)
Precision 36.431% 97.000% TP/(TPþFP)
Speciﬁcity
TN rate 99.826% 99.997% TN/(FPþTN)
The number of TP and FP variants was determined for both methods, as well as the number of base pairs identical to the reference genome (TNs) and number
of variants missed when comparing both methods (FNs). Sensitivity and speciﬁcity variables were calculated with the formulas indicated in the right column.
FN, false negative; FP, false positive; PGM, Personal Genome Machine; smMIP, single-molecule molecular inversion probe; SNP, single nucleotide poly-
morphism; TN, true negative; TP, true positive.
Cancer Hotspot Detection Using smMIPscurrent analysis (Supplemental Table S5). The mutant allele
frequencies of all mutations identiﬁed by NGS in both ap-
proaches are comparable with the exception of one 45-bp
deletion in KIT (Figure 3E), which could be due to prefer-
ential ampliﬁcation in the AmpliSeq-PGM strategy. In
addition, the results from the sex controls were fully
concordant (data not shown). These data, together with the
other sequencing data obtained during implementation (see
above), show that the smMIP approach is at least as sensi-
tive as the Ampliseq-PGM and Sanger-based sequencing
approaches (requirement iii).
Although the detection of clinically relevant mutations is
comparable, the number of false-positive variants with an
allele frequency >5% is signiﬁcantly reduced in the smMIP-
NextSeq500 approach (on average >10-fold reduction,
P < 0.0001) (Figure 4A), although the total sequenced
target region is >67% and 154% larger compared with the
two Ampliseq panels. The false-positive rate and precision
(Table 2) clearly show that the smMIPs-NextSeq500
approach outperforms the AmpliSeq-PGM strategy,A
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Figure 5 Minimal read depth requirements using SMT-derived unique read dep
minimal criteria for mutation calling (1% mutant allele frequency and 3 mutant
indicates the probability to fulﬁll the variant calling criteria (the probability of suc
read depth (the number of trials). The dashed line depicts the 95% probability lev
unique reads) covering a locus to reliably (approximate probability of a false-negat
binned, and matched lower limits of mutation detection are shown per bin (eg,
determined; smMIP, single-molecule molecular inversion probe; SMT, single mole
The Journal of Molecular Diagnostics - jmd.amjpathol.orgthereby meeting requirement iv. The near lack of false
positives in the smMIP protocol is probably due to a com-
bination of factors and may partly be attributed to the dif-
ference in sequencing technologies (Ion Torrent versus
Illumina), but may also be due to the merging of PCR du-
plicates (sequence reads with identical SMTs) into
consensus reads, thereby largely eliminating PCR and
sequencing artifacts. As expected, consensus building using
the SMT feature reduces the number of false-positive vari-
ants per read by approximately eightfold (Figure 4B). This
clearly demonstrates the enormous advantage of SMTs in
library preparation and data analysis.
Because of the relatively high level of false-positive calls
with an allele frequency of 1% to 5%, the AmpliSeq-PGM
approach does not allow for the reliable detection of variants
<5%. Because the SMTs in the smMIP-NextSeq500 strat-
egy greatly reduce the number of false-positive variants, we
analyzed whether this strategy is suitable to detect patho-
genic variants in the lower frequency range. With the use of
the smMIP procedure, the total number of identiﬁed variantsB
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Figure 6 Validation of the smMIP approach by
parallel sequence analysis of 67 clinical samples in
a clinical diagnostic setting over a period of 6
weeks. A: An overview of our routine diagnostic
sequence analysis ﬂow of cancer hotspot regions
using sequence analysis based on Ampliseq-PGM
(a total of two panels) or Sanger (ﬁve different
amplicons), of which one is executed depending
on the speciﬁc clinical request, and the smMIP-
NextSeq500ebased single-reaction set-up for all
clinical requests. In Ampliseq-PGM and Sanger
strategy, all steps are performed manually,
whereas the smMIP-based diagnostics is semi-
automated for library preparation and automated
for variant detection on NGS analysis (indicated in
orange). Clinical samples are batched and analyses
are performed two or three times a week (blue
arrows and text directly adjacent to ﬂow).
B: Parallel sequencing as described was performed
in a clinical diagnostic setting for a total of 67
samples, also Figure 3E. The read depth at relevant
hotspot positions was determined and judged
sufﬁcient or insufﬁcient to reliably exclude the
presence of mutations (cutoffs in Figure 5B), also
taking the estimated tumor load into account.
Partially insufﬁcient represents samples for which
the read depth was sufﬁcient in only a subset of
relevant hotspots, whereas the pathogenic muta-
tion was identiﬁed. Sanger-based sequence anal-
ysis was judged sufﬁcient in case a sequencing
proﬁle could be generated. C: The lower limit for
reliable mutation detection was determined for all
relevant hotspot positions in 67 clinical samples.
For each sample, sorted by the year of tissue
sampling, the DNA concentration is indicated on
the y axis. The lower detection limit is shown by
color. The lower limit for reliable mutation
detection is indicated as ND when insufﬁcient read
depth was obtained. D: The turnaround time for all
67 clinical request is depicted for both the
Ampliseq-PGM and Sanger-based approach and the
smMIP-NextSeq500 strategy. ND, not determined;
NGS, next-generation sequencing; PGM, Personal
Genome Machine; smMIP, single-molecule molec-
ular inversion probe.
Eijkelenboom et alin the lower frequency range (1% to 5%) is 1 in half of the
samples tested (Supplemental Figure S2). In a subset of
samples we identiﬁed a large number of variants in the 1%
to 5% range. Nearly all variants are C>T transitions (10
samples in our series of 67 samples contain 10 C:G>T:A
variants), that reﬂect formalin-induced deamination of
cytosine residues and are therefore only detected with either
the sense or antisense targeting smMIP (Figure 4C). These
data show that it is also feasible to conﬁdently detect low-
level mutations (1% to 5%) using the smMIP strategy, as
previously shown by Hiatt et al.11
There is an additional important advantage of the SMTs.
When sequence analyses include PCR duplicates, this may
result in false-negative results due to overestimation of the
actual number of analyzed molecules. This is especially
relevant in the context of poor-quality FFPE-derived gDNA.
The use of SMTs to generate read depth in unique reads thus860provides an exact measure of the number of analyzed input
DNA molecules (library complexity). With the use of the
binomial distribution, we calculated the probability to
identify a mutation, depending on the unique read depth and
an assumed mutant allele frequency in the specimen
(Figure 5A). These probabilities provide an approximation
of the minimum read depth thresholds to exclude mutations
above a certain allele frequency, with a certainty of >95%
(Figure 5B).
We used these minimum read depth levels to determine
whether sufﬁcient DNA molecules were sequenced to reli-
ably analyze the hotspots relevant for the speciﬁc clinical
request in our series of 67 samples. These data were also
interpreted in the context of estimated tumor load (percentage
of neoplastic cells) assessed by a pathologist. We performed
this analysis for all hotspot regions relevant for the speciﬁc
clinical request and generated a full report, which wasjmd.amjpathol.org - The Journal of Molecular Diagnostics
Cancer Hotspot Detection Using smMIPscompared with our clinical report generated by the routine
Ampliseq/PGM- or Sanger-based approach (Supplemental
Table S5). Figure 6A schematically depicts both our cur-
rent diagnostic ﬂow and the smMIP-based approach.
Concordant reports were generated in 64 of 67 cases (96%),
of which two generated insufﬁcient reads in both methods to
provide a conclusion. In our automated smMIP procedure
library preparations are standard and performed in duplicate
for all samples, which are normally independently analyzed.
However, because these library preparations are independent,
the sequence data may be merged (simultaneously analyzed).
Merging of two to four replicates was required to obtain
sufﬁcient unique read depth in 6 of 64 concordant cases.
Sufﬁcient read depth was deﬁned in the context of estimated
tumor load and based on calculations in Figure 5B. For two
clinical samples the AmpliSeq-PGM diagnostic analysis
generated insufﬁcient total read depth, whereas the smMIP-
NextSeq500 analysis provided sufﬁcient unique read depth
to report results. In one case, insufﬁcient unique reads were
generated by the smMIP-NextSeq500 approach to analyze
all relevant codons and reliably exclude the presence of a
mutation, whereas total read depth in the AmpliSeq-PGM
diagnostic approach was adequate (Figure 6B). With the
use of these constraints the number of dropouts using the
smMIP-NextSeq500 approach during the validation period is
lower than the AmpliSeq-PGM approach (requirement v).
Note that the minimal read depth requirements for the
AmpiSeq-PGM approach are estimations based on empirical
(dilution) experiments, whereas those for the smMIP method
are statistical calculations based on the actual number of
unique molecules and therefore are more reliable.
To be able to predict up front which samples require
merged data analysis, thus requiring triplicate or even
quadruplicate library preparations, we related the obtained
unique read depth for all samples to the DNA concentration
and age of the sample. A low concentration of extracted
gDNA is predictive for suboptimal results, as well as an
extended period between tissue sampling and DNA isolation
(Figure 6C). From these result we decided to perform trip-
licate analyses for samples with a DNA concentration <5
ng/mL and the period between tissue sampling and DNA
isolation of >2 years.
We compared the TAT of the smMIP-NextSeq500 and
the AmpliSeq-PGM and Sanger approach during our vali-
dation period (from request until diagnostic report). The
TAT on average increases with one working day using the
smMIP-based approach in our diagnostic workﬂow
(Figure 6D). This delay is due to the transfer of the sample
for the robotized protocol (K. Neveling, A.R. Mensenkamp,
R.C. Derks, et al, unpublished data), which is therefore less
time-efﬁcient than the manual protocol, but also due to the
reduction to two NextSeq 500 sequencing runs per week,
instead of three PGM runs. Using the smMIP strategy, 66 of
67 clinical requests (99%) were handled 7 working days.
After ofﬁcial implementation of the smMIP approach for all
our routine diagnostic mutational analyses (since DecemberThe Journal of Molecular Diagnostics - jmd.amjpathol.org2015), the turnaround time of 94% of 79 clinical requests in
January 2016 is 7 working days, thus fulﬁlling our last
requirement (vi).Discussion
Over the past decade, there has been a rapid rise in the need
for sequence analysis of hotspot regions in oncogenes.
Molecular diagnostic analysis of tumor tissue is used to
reﬁne diagnosis or to stratify patients for personalized
treatment with targeted therapies. This requires sensitive and
reliable sequence analysis of limited amounts of low-quality
gDNA, isolated from FFPE samples. To analyze multiple
relevant loci simultaneously, NGS approaches using hy-
bridization- or PCR-based target enrichment methods have
been developed. Although PCR-based methods generally
require less input DNA, sequencing of PCR duplicates may
result in an overestimation of library complexity and, thus,
analytical sensitivity. To reliably detect and, equally
important, to exclude the presence of mutations, accurate
assessment of sequence library complexity is required. Here,
we describe the results of the implementation and validation
of SMT using smMIPs in routine molecular diagnostics of
routinely processed FFPE tumor tissue. We developed a
smMIP pool that targets >95% of all hotspot regions in 23
genes by a minimum of two separate smMIPs, analyzing all
41 hotspot regions in one single reaction. This approach
fulﬁlled all our prospectively deﬁned validation re-
quirements and has proven to be superior to Sanger
sequencing and Ampliseq-PGM sequencing. Therefore, we
have now implemented this smMIP-based target enrichment
in our routine sequence analyses pipeline in our laboratory.
This also includes sequence analysis to identify somatic
mutations in tumor suppressor genes such as BRCA1,
BRCA2 (R.D.A. Weren, A.R. Mensenkamp, M. Simons, A.
Eijkelenboom, et al, unpublished data shown), TP53, and
CDKN2A (A.E. and B.B.J.T., unpublished data).
The smMIPs in our panel were designed to target
genomic regions of exactly 112 bp. Including extension and
ligation probes, the total targeted region is 152 bp. Larger
regions are more efﬁcient in probe design and sequencing,
but, because most of our clinical sequence requests are
performed on fragmented DNA isolated from FFPE tissue, a
smaller target design is more beneﬁcial. Although smaller
regions may be more efﬁcient using FFPE-derived DNA,
designing these is more complex and the capture and
detection of insertions and deletions may be complicated.
Important in this respect is that reads spanning deletions and
duplications should not be removed from the analysis due to
too stringent alignment criteria, such as the absolute and
relative number of matching bases, or a strict requirement of
reads to include sequences of both the extension and ligation
probe (ie, with an NGS read length of 150 bp this require-
ment is not fulﬁlled in case of insertions or duplications
>10 bp). We have extensively tested our approach and861
Eijkelenboom et aldemonstrated that our design is capable of reliably detecting
insertions (42 bp) and deletions (63 bp).
During the entire implementation period we tested >200
samples using the smMIP approach, and all sequence re-
sults were concordant with other sequencing methods. In
addition, we validated the smMIP approach side by side to
our previous diagnostic sequencing strategies for all our
diagnostic sequence request over a period of several weeks.
We achieved a TAT of 7 working days for >94% of the
clinical requests. In total, 42 mutations were identiﬁed in 67
clinical samples using our previous diagnostic strategies
and conﬁrmed using the smMIP approach. One of the true
advantages of SMT is highlighted by the seven samples for
which single capture events (library preparations) resulted
in insufﬁcient unique read depth to conﬁdentially call the
absence of variants (true negative), indicating low library
complexity for these samples. For six of these samples this
could be remedied by combining the data of replicate as-
says. For the remaining sample combined analysis did not
provide sufﬁcient unique read depth, indicating that insuf-
ﬁcient genomic molecules were present in this sample to
generate a sufﬁciently complex sequence library. This
sample was sufﬁciently sequenced using the Ampliseq-
PGM approach (average total read depth of >500), but
this raises the question how many genomic molecules were
ampliﬁed during PCR. The suboptimal sequence results of
these seven cases would have gone unnoticed in the
absence of SMTs and highlight the importance of unique
read depth to assess library complexity versus total read
depth.
smMIP approach not only provides a better sense of
reliability but also results in a notable reduction of identiﬁed
false-positive variants compared with the Ampliseq-PGM
approach. In our diagnostic ﬂow, all called variants are al-
ways manually reviewed (and curated) before a report is
authorized. By generating consensus reads using the SMTs
hardly any false-positive variants are called (Figure 4A),
saving considerable amounts of hands-on analysis time per
sample. This also allows for the detection of mutations in
clinical FFPE samples with allele frequencies as low as 1%
and exclude false negatives with a lower limit of 3%. These
sensitivities are necessary for samples with a low tumor load
(<20%, notably lung cancer biopsies), the detection of
therapy-induced resistance mutations such as EGFR
p.T790M,14 and some differential diagnostic requests (eg,
mosaic somatic mutations in overgrowth syndromes).15 An
additional beneﬁt of the smMIPs is the DNA strand-speciﬁc
capture, because it allows for discrimination of genuine
C:G>T:A transition mutations and those occurring due to
deamination after sample collection. The latter only occur
on the cytosine-containing strand and are therefore detected
differentially by individual smMIPs targeting both DNA
strands. The distinction between these artifacts and genuine
C:G>T:A mutations is relevant for FFPE samples that may
contain a substantial number of these artifacts, especially in
DNA isolated from older tissue specimens.862Besides a superior performance in variant detection, the
smMIP approach provides additional advantages. First,
existing gene panels are easily adaptable by adding smMIPs
targeting new regions to an already optimized smMIP pool.
Second, because the smMIP library preparation protocol is
simple, it allows for straightforward library preparation
automation. This and our automated mapping and variant
calling solution (K. Neveling, A.R. Mensenkamp, R.C.
Derks, et al, unpublished data) reduces hands-on time, the
risk of sample handling errors, and makes this method
scalable to accommodate a further increase in clinical re-
quests. Third, although not our main incentive, the smMIP
approach is highly cost-effective. Whereas prices for com-
mercial library preparation kits are ﬁxed per sample, the
smMIP method only has relatively high initial costs
(151 smMIP probes  approximately V10 per
probe Z approximately V1500) with low additional costs.
A single order of smMIP probes is sufﬁcient for >106
samples, and additional reagents required for library prep-
aration are relatively inexpensive, adding up to a total of
<V10 per sample for library preparation (depending on
ordered volumes). Therefore, smMIP-based library prepa-
rations seem especially suited for routine sequence analysis
(on a large number of samples), that justify a high initial
investment to order and optimize the smMIP probes. In our
workﬂow, most costs required to analyze a sample are the
sequencing costs, and those are minimized in our setting by
combining the requests of the here described smMIP-based
CHP with other smMIP-based sequence analyses, such as
hereditary and somatic testing of BRCA1/2 [(K. Neveling,
A.R. Mensenkamp, R.C. Derks, et al, unpublished data
shown) and (R.D.A. Weren, A.R. Mensenkamp, M. Simons,
A. Eijkelenboom, et al, unpublished data)]. This also dem-
onstrates that not only hotspot positions but also entire
(tumor suppressor) genes can be reliably sequenced using
smMIPs, as has been published for hereditary testing using
MIPs.16 Finally, preliminary results and published data also
suggest that the smMIP approach can be extended beyond
sequence analysis to detect copy number variants in our set
up (K. Neveling, A.R. Mensenkamp, R.C. Derks, et al,
unpublished data), which has been published for MIPs in
general17 and known clinically relevant fusion transcripts
using a similar automated workﬂow (results not shown).Conclusions
We show that target enrichment using MIPs in combination
with single-molecule tags is highly sensitive and provides a
true sense of reliability of sequence results. This is especially
important when analyzing low amounts of DNA or DNA of
poor quality that is daily practice in the routine diagnostics of
FFPE tissue. Other (clinical) applications, like the sequencing
of cell-free tumor DNA isolated from blood plasma (liquid
biopsies), will undoubtedly beneﬁt from target enrichment
strategies using single-molecule tags.jmd.amjpathol.org - The Journal of Molecular Diagnostics
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